Brilinta Wins Indication in Recurrent Stroke Prevention

(MedPage Today) -- FDA granted ticagrelor (Brilinta) an indication for secondary prevention in stroke and high-risk transient ischemic attack (TIA), AstraZeneca announced.
The P2Y12 inhibitor is to be used as part of a dual antiplatelet regimen...